Gyre Therapeutics Inc (GYRE) — Titan Protect Analysis

GYRE

Gyre Therapeutics Inc

Healthcare · ·

$6.29

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$539M

Total market value of the company

Trailing P/E

N/A

Forward P/E

92.50

Based on estimated future earnings — lower means cheaper

Rev Growth

+2.1%

Year-over-year revenue change

Profit Margin

-5.4%

How much profit the company keeps from each dollar of revenue

ROE

-3.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$18.00

+186% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 3 analysts covering this stock

About Gyre Therapeutics Inc

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the

https://www.gyretx.com

Country: United States Employees: 625 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.070

Positive but modest risk-adjusted returns

Kelly Fraction

-0.0054

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.367

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-24.6%

Historical annualised return based on price data

Max Drawdown

-66.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

5.28

Significantly more volatile than the market

52W High

$9.42

33% below the year high

52W Low

$5.44

16% above the year low

Avg Volume

100,182

Average daily shares traded — higher means easier to buy and sell

Short Ratio

23.8

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.08

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.60

Moderate leverage — manageable

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

95.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-30.2%

Profit from core operations before interest and tax

Free Cash Flow

$10M

Positive — the business generates more cash than it spends

Revenue (TTM)

$117M

Total revenue over the last 12 months

Net Income

$-6,362,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$20.00

Target Median

$18.00

Target Low

$18.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go